NCT00104078View on ClinicalTrials.gov

Study Evaluating MYO-029 in Adult Muscular Dystrophy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

February 28, 2005

Study Completion Date

January 31, 2007

Conditions
Becker Muscular DystrophyFacioscapulohumeral Muscular DystrophyLimb-Girdle Muscular Dystrophy
Interventions
DRUG

MYO-029

Trial Locations (9)

20010

Washington D.C.

Unknown

Kansas City

Boston

St Louis

Rochester

Columbus

Dallas

Salt Lake City

21287-7519

Baltimore

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00104078 - Study Evaluating MYO-029 in Adult Muscular Dystrophy | Biotech Hunter | Biotech Hunter